Octapharma Ag International Business Unit Haematology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Octapharma: Final Data From the NuProtect Study Published on the Immunogenicity of Nuwiq in Previously Untreated Patients With Severe Haemophilia A
in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal
Thrombosis and Haemostasis (Liesner RJ et al. Simoctocog Alfa (Nuwiq
) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623).
The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq
. The study recruited patients of any age and ethnicity at 38 sites in 17 countries and followed patients for 100 exposure days or up to 5 years. With enrolment of 110 patients, the NuProtect study was the largest clinical study to inv ....

United States , Switzerland General , United Kingdom , City Of , Nordrhein Westfalen , Kostenloser Wertpapierhandel , Larisa Belyanskaya , Anthony Chan , Ivana Spotakova , Olaf Walter , Professor Of Paediatrics At Mcmaster University , Octapharma Ag International Business Unit Haematology , Previously Untreated Patients , Severe Haemophilia , Final Results , Great Ormond Street Hospital , Board Member , Mcmaster University , Adv Hematol , Business Unit Haematology , ஒன்றுபட்டது மாநிலங்களில் , சுவிட்சர்லாந்து ஜநரல் , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , னோற்ர்ேன் வெஸ்ட்ஃபாலன் , அந்தோணி சான் ,